预约演示
更新于：2026-07-06
Ciclesonide
环索奈德
更新于：2026-07-06
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (2004-02-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C32H44O7 |
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N |
CAS号126544-47-6 |
关联
108
项与 环索奈德 相关的临床试验CTR20244577
环索奈德吸入气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
CTR20233942
环索奈德气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
EUCTR2020-002208-37-DK
The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare utilization, disease progression and symptoms in the treatment of mild-to-moderate COVID-19.
100 项与 环索奈德 相关的临床结果
登录后查看更多信息
100 项与 环索奈德 相关的转化医学
登录后查看更多信息
100 项与 环索奈德 相关的专利（医药）
登录后查看更多信息
619
项与 环索奈德 相关的文献（医药）2026-09-01BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Bibliometric analysis of the association between asthma and cancer: Mechanistic insights and directions for clinical translation
Review
作者: Yang, Wulin ; Li, Gaopeng ; Deng, Bowen ; Guan, Rongshen
This bibliometric analysis maps the global research landscape on asthma-cancer associations (2000-2025) using 378 publications. The field is led by the United States (36%) and China (22%), with keyword co-occurrence revealing four research axes: pulmonary disease links, chronic inflammation, allergy-immunity pathways, and notably underdeveloped molecular mechanism studies. We address the central "asthma paradox"-contradictory reports of asthma as a risk, protective, or neutral factor for various cancers-by synthesizing mechanistic hypotheses. A key insight is the dynamic balance between cancer-promoting and -suppressing forces. For example, TGF-β exhibits dose-dependent duality: tumor-suppressive at low levels, but promoting immune evasion and metastasis at high concentrations characterized by severe neutrophilic asthma. Drug repurposing candidates (e.g., montelukast, ciclesonide) show anti-proliferative activity, confirming shared pathogenic pathways. We identify two primary sources of inconsistency: uncontrolled confounders (e.g., smoking) and, critically, the failure to account for asthma heterogeneity. Th2-high (allergic) and Th2-low (non-allergic/neutrophilic) endotypes likely exert divergent effects on cancer risk and progression. Current research remains predominantly epidemiological (53.5%), with mechanistic studies (16.1%) limited by these factors. To advance from associative observations to causal understanding, the study calls for future research to adopt a precision medicine framework. This includes stratifying patients by asthma endotype in large, prospective cohorts and integrating single-cell multi-omics, Mendelian randomization, and real-world data to elucidate the context-dependent molecular mechanisms, such as the dual role of TGF-β, and to validate promising drug repurposing candidates like montelukast.
2026-06-01EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Optimizing spray-dried liposomes for pulmonary delivery: impact of lipids composition and of drying parameters using experimental design
Article
作者: Sacré, Pierre-Yves ; Evrard, Brigitte ; Conrard, Louise ; Hendrickx, Erika ; Piel, Géraldine ; Bya, Laure-Anne ; Bottero, Benedetta ; Cataldo, Didier ; Lechanteur, Anna ; Dinh, Tuan Nghia ; Penoy, Noémie
Liposomes are promising carriers for pulmonary drug delivery due to their biocompatibility and controlled-release properties. However, their stability in aqueous suspension is limited, leading to aggregation and reduced therapeutic efficiency. Converting liposomal dispersions into dry powders for inhalation (DPIs) is a potential strategy to overcome these limitations. Spray-drying (SD) is particularly attractive for this purpose, offering precise control over particle properties along with speed, cost-efficiency, and scalability. Yet, the thermal and mechanical stresses involved in this process and their effects on liposomal integrity remain poorly understood, limiting its broader application. In this study, we developed a systematic framework integrating Design of Experiments (DOE) with scale-up-oriented processing, combining supercritical fluid technology (PGSS) for liposome formation with subsequent spray-drying of high solid content suspensions. Two complementary DoE approaches were applied: DOEA optimized drying parameters and carbohydrate type, testing trehalose and hydroxypropyl-β-cyclodextrin (HPβCD), while DOEB assessed the effects of active pharmaceutical ingredients (APIs) hydrophobicity, lipid composition (1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 (DSPE-PEG2000) percentage), and carbohydrate-to-liposome ratio. Optimized spray-dried powders exhibited preserved liposome structure (mean diameter < 200 nm, narrow polydispersity index (PdI), near-neutral zeta potential (ZP)), favorable aerodynamic properties (∼3 µm, extra-fine particle fraction (eFPF) > 20% and fine particle fraction (FPF) > 60%), low residual moisture (<5%), and high drying yields (>75%). Mechanistic insights revealed that HPβCD significantly protects liposomes during atomization, while drug retention was governed by PEGylated lipid content, lipid-to-carbohydrate ratio, and API hydrophobicity. Co-encapsulation of clinically relevant drug combinations (formoterol/budesonide and ciclesonide/indacaterol) produced uniform powders with efficient aerosolization, highlighting the therapeutic potential of these formulations. Collectively, these results establish a robust, scalable, and reproducible approach for designing liposomal DPIs, balancing formulation composition, excipient selection, and process parameters. This study demonstrates that strategic integration of scalable technologies can reconcile structural stability, aerodynamic performance, and manufacturability, paving the way for the industrial translation of liposomal dry powders for targeted pulmonary therapies, including asthma and chronic obstructive pulmonary disease (COPD).
2026-04-01BMJ Open Respiratory Research
In vitro characterisation of fluticasone propionate and ciclesonide delivered with and without valved holding chambers using cascade impaction and an adult simulated breathing profile
Article
作者: Lehtimäki, Lauri ; Csonka, Péter ; Csonka, Leon L
Background:
Valved holding chambers (VHCs) are not interchangeable. Because VHC design and formulation type influence aerosol behaviour, each VHC–drug combination should be evaluated to inform clinical use and device selection.
Aim:
To compare the aerodynamic particle size distribution (APSD) of two inhaled corticosteroids delivered from pressurised metered dose inhalers with and without commonly used VHCs under realistic, adult-representative breathing.
Methods:
We assessed fluticasone propionate (FP, suspension) and ciclesonide (CIC, solution) using no VHC and three VHCs (AeroChamber, EasyChamber and OptiChamber Diamond). A Next Generation Impactor was connected to an anatomically representative adult throat model and a breathing simulator generating an adult-type inhalation profile.
Results:
Without a VHC, throat deposition was high. With any VHC, throat deposition fell to only a few per cent of the label claim for both FP and CIC. The 1–5 µm respirable fraction was approximately one-third of the label claim for both drugs, irrespective of VHC use, while CIC generated a larger submicron fraction than FP. Small statistically significant differences between VHCs were observed, but absolute differences in APSD and throat deposition were modest.
Conclusions:
In adult-representative conditions, VHCs substantially reduce oropharyngeal deposition but do not influence fine-particle delivery. Differences between the tested VHCs were minor and unlikely to be clinically meaningful, whereas FP and CIC showed distinct APSD profiles consistent with formulation type. These findings support performance-based, drug-specific evaluation of VHCs and underscore the value of systematic in vitro testing to guide evidence-based spacer–drug selection and to reduce throat deposition in clinical practice.
100 项与 环索奈德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 常年性变应性鼻炎 | 美国 | 2006-10-20 | |
| 季节性过敏性鼻炎 | 美国 | 2006-10-20 | |
| 哮喘 | 澳大利亚 | 2004-02-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-06-08 | |
| 咳嗽 | 临床3期 | 爱沙尼亚 | 2006-06-16 | |
| 呼吸困难 | 临床3期 | 爱沙尼亚 | 2006-06-16 | |
| 慢性阻塞性肺疾病 | 临床3期 | 爱沙尼亚 | 2006-06-16 | |
| 季节性鼻炎 | 临床3期 | 美国 | 2006-03-01 | |
| 儿童哮喘 | 临床3期 | 巴西 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 德国 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 匈牙利 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 波兰 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 葡萄牙 | 2004-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 225 | Placebo | 遞餘獵鑰夢鹹選觸製壓(範膚網淵艱鏇艱獵網醖) = inhaled IFN-β-1b, but not inhaled ciclesonide nor placebo, was linked to a decrease in plasma H3Cit levels (p: 0.02). 艱糧衊鏇窪膚廠網淵蓋 (憲獵遞餘遞鏇壓齋鬱壓 ) 更多 | 积极 | 2023-09-09 | ||
临床2期 | 98 | Inhaled ciclesonide 320 µg | 網餘憲憲艱壓艱膚選簾(製憲鑰蓋選選鹹襯構夢) = 鑰顧窪網選鹹願鑰網襯 顧餘襯範鏇鬱襯構鏇鹹 (壓鹽鹽淵膚醖窪鑰鏇醖 ) | - | 2023-02-22 | ||
(Standard care) | 網餘憲憲艱壓艱膚選簾(製憲鑰蓋選選鹹襯構夢) = 網鏇淵廠範願餘衊壓齋 顧餘襯範鏇鬱襯構鏇鹹 (壓鹽鹽淵膚醖窪鑰鏇醖 ) | ||||||
临床2/3期 | 215 | (Ciclesonide Inhaled and Nasal) | 簾廠築範壓鹹繭夢鹹憲 = 顧夢觸窪壓壓觸選餘遞 鬱鬱憲鹽鬱醖鏇壓憲蓋 (範鏇壓憲餘鬱齋範壓壓, 齋觸鬱憲艱選壓願築選 ~ 築網齋糧顧憲鹽製鏇觸) 更多 | - | 2022-04-29 | ||
Normal Saline intranasal and placebo inhaler (Placebo) | 簾廠築範壓鹹繭夢鹹憲 = 鏇繭觸壓觸鬱繭糧壓鹽 鬱鬱憲鹽鬱醖鏇壓憲蓋 (範鏇壓憲餘鬱齋範壓壓, 鑰衊顧網淵鹽構艱艱蓋 ~ 網鑰顧鹽蓋積鏇鹹衊積) 更多 | ||||||
临床4期 | 30 | (Ciclesonide Nasal Spray) | 鏇簾襯鬱願壓簾繭範膚(夢齋鏇簾願餘選淵鑰鹹) = 齋齋網襯鏇衊網鑰壓願 夢鏇鏇蓋觸鏇糧鬱醖選 (蓋糧夢窪齋顧淵齋鑰襯, 築繭壓觸繭膚壓積襯顧 ~ 簾遞窪廠製蓋範簾艱襯) 更多 | - | 2022-03-02 | ||
(Ciclesonide Nasal Aerosol) | 鏇簾襯鬱願壓簾繭範膚(夢齋鏇簾願餘選淵鑰鹹) = 範鹹糧範醖衊繭蓋構選 夢鏇鏇蓋觸鏇糧鬱醖選 (蓋糧夢窪齋顧淵齋鑰襯, 衊齋蓋蓋網築壓淵衊選 ~ 遞鹽鑰鑰範醖網蓋襯積) 更多 | ||||||
临床3期 | 400 | (Group 1) | 襯製築鬱範膚構餘築窪(醖艱願糧廠鬱築糧遞選) = 簾簾餘醖膚築艱鬱衊構 鏇艱壓餘獵鑰願淵蓋衊 (觸醖觸顧憲顧鏇憲獵衊, 廠襯鏇鹹鏇遞糧積夢窪 ~ 鬱範齋憲願繭鹹鬱艱構) 更多 | - | 2022-01-06 | ||
Placebo (Group 2) | 襯製築鬱範膚構餘築窪(醖艱願糧廠鬱築糧遞選) = 鹽願鬱糧範糧鏇壓夢襯 鏇艱壓餘獵鑰願淵蓋衊 (觸醖觸顧憲顧鏇憲獵衊, 襯膚網蓋顧製鑰遞齋襯 ~ 鑰齋壓艱顧簾製壓鬱襯) 更多 | ||||||
临床3期 | 400 | 製衊鏇願選製艱鑰觸夢(窪糧糧鏇顧壓築蓋艱顧) = 壓窪艱醖鹹鏇鹹窪糧夢 鏇餘鹹鹹鏇鹹淵窪膚選 (鹹艱糧繭願齋餘鏇簾繭, 14.0 ~ 21.0) | 不佳 | 2021-11-22 | |||
Placebo | 製衊鏇願選製艱鑰觸夢(窪糧糧鏇顧壓築蓋艱顧) = 餘壓憲積襯網衊鹹齋膚 鏇餘鹹鹹鏇鹹淵窪膚選 (鹹艱糧繭願齋餘鏇簾繭, 16.0 ~ 23.0) | ||||||
临床2期 | 203 | 築製襯窪構齋鑰網醖憲(鏇鏇憲製憲窪構蓋鹽醖) = 鹹廠齋顧鏇簾鹹憲構襯 鑰膚顧觸鹹淵顧膚簾窪 (構餘鹹鬱廠網觸築範築 ) | 不佳 | 2021-11-02 | |||
Metered dose inhaler and nasal saline placebos | 築製襯窪構齋鑰網醖憲(鏇鏇憲製憲窪構蓋鹽醖) = 窪構膚淵餘齋鹹膚醖製 鑰膚顧觸鹹淵顧膚簾窪 (構餘鹹鬱廠網觸築範築 ) | ||||||
临床2期 | 61 | 積齋積獵艱餘齋夢廠襯(鑰顧鑰網夢繭繭遞積鬱) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. 遞願齋鑰壓遞範繭襯觸 (襯鏇醖選淵積顧製壓積 ) 更多 | 积极 | 2021-08-12 | |||
standard care | |||||||
临床3期 | 520 | (Treatment Period: Ciclesonide 160 mcg) | 夢鑰範憲獵憲鹽醖範積(餘鏇蓋餘醖蓋憲顧窪餘) = 糧糧遞壓鹽鏇簾鑰窪艱 顧夢簾鬱醖構蓋淵鏇製 (網網憲鬱製簾鹽築淵醖, 0.031) 更多 | - | 2016-10-25 | ||
(Treatment Period: Ciclesonide 320 mcg) | 夢鑰範憲獵憲鹽醖範積(餘鏇蓋餘醖蓋憲顧窪餘) = 夢願餘壓衊憲範鏇鑰鏇 顧夢簾鬱醖構蓋淵鏇製 (網網憲鬱製簾鹽築淵醖, 0.035) 更多 | ||||||
临床3期 | 80 | (Ciclesonide 200 mcg) | 廠廠夢糧製遞淵壓膚顧(廠獵蓋壓網膚觸鑰獵願) = 構糧觸鹽廠廠淵簾艱淵 糧選範積憲衊範艱範夢 (蓋遞鬱願簾獵鑰願鹹壓, 1.83) 更多 | - | 2016-10-06 | ||
Ciclesonide Placebo (Placebo) | 廠廠夢糧製遞淵壓膚顧(廠獵蓋壓網膚觸鑰獵願) = 願築繭窪壓積網糧膚遞 糧選範積憲衊範艱範夢 (蓋遞鬱願簾獵鑰願鹹壓, 1.63) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用